NEW YORK (GenomeWeb News) – Abbott yesterday said that it will partner with Pfizer on a molecular diagnostic test to screen non-small cell lung cancer tumors for the presence of gene rearrangements.
Pfizer is developing a drug that selectively targets cancer-causing genes implicated in the progress of many cancers, the firms said in a statement. For patients to be eligible to receive the drug candidate, a particular genetic translocation known to be present in NSCLC tumors and others cancers, but not in normal cells, must be identified in the tumor sample.
Abbott will develop a companion diagnostic test that will determine if a patient's genetic status makes them eligible for selection in future clinical trials of the compound, PF-02341066.
"Pfizer's novel compound for treating non-small cell lung cancer appears to be ideally suited to individualized therapy," said Stafford O'Kelly, head of Abbott's molecular diagnostics business, in a statement.